Novo Nordisk (NVO) announced that the Food and Drug Administration has approved Ozempic to reduce the risk of kidney disease worsening, kidney failure, and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. This approval, along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular events in adults also with known heart disease, establishes Ozempic “as the most broadly indicated glucagon-like peptide-1 receptor agonist in its class,” the company said in a statement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Continues Aggressive Share Repurchase Programme
- Contact Levi & Korsinsky LLP by March 25, 2025 Deadline to Join Class Action Against Novo Nordisk A/S(NVO)
- Novo Nordisk criticized for not disclosing payments to health groups, STAT says
- Unusually active option classes on open January 24th
- Morning Movers: American Express and Verizon trend higher following Q4 results